Hepatic Impact of Etrasimod for Treatment of Moderately to Severely Active Ulcerative Colitis: An Integrated Safety Summary From the Etrasimod Ulcerative Colitis Clinical Program

被引：0
|
作者：
Regueiro, Miguel [1 ]
Vermeire, Severine [2 ]
Rubin, David T. [3 ]
Dubinsky, Marla C. [4 ]
Hart, Ailsa [5 ,6 ]
Wu, Joseph [7 ]
Green, Jesse [8 ]
Woolcott, John C. [8 ]
Gorelick, Kenneth J. [8 ]
McDonnell, Aoibhinn [9 ]
Lazin, Krisztina [10 ]
Peyrin-Biroulet, Laurent [11 ,12 ]
机构：
[1] CaseWestern Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH USA
[2] Univ Ziekenhuis Leuven, Leuven, Vlaams Brabant, Belgium
[3] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA
[4] Mt Sinai Kravis Childrens Hosp, New York, NY USA
[5] St Marks Hosp, London, England
[6] Imperial Coll, London, England
[7] Pfizer Inc, Cambridge, MA USA
[8] Pfizer Inc, Collegeville, PA USA
[9] Pfizer Ltd, Sandwich, England
[10] Pfizer AG, Zurich, Switzerland
[11] Lorraine Univ, Last Inserm U954, Vandoeuvre Les Nancy, Lorraine, France
[12] Lorraine Univ, CHU Nancy, Vandoeuvre Les Nancy, Lorraine, France
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1072
引用
收藏
页码：S816 / S817
页数：2
相关论文
共 50 条
  • [1] Impact of Etrasimod on Blood Pressure and Hypertension: Data From the Etrasimod Ulcerative Colitis Clinical Program
    Vermeire, Severine
    Rubin, David T.
    Peyrin-Biroulet, Laurent
    Dubinsky, Marla C.
    Regueiro, Miguel
    Irving, Peter M.
    Goetsch, Martina
    Lazin, Krisztina
    Wu, Joseph
    Modesto, Irene
    Woolcott, John C.
    McDonnell, Aoibhinn
    Rabbat, Christopher J.
    Yarur, Andres J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S675 - S675
  • [2] Etrasimod for the treatment of ulcerative colitis
    Wils, Pauline
    Peyrin-Biroulet, Laurent
    IMMUNOTHERAPY, 2023, 15 (05) : 311 - 321
  • [3] Therapeutic Potential of Etrasimod in the Management of Moderately-to-Severely Active Ulcerative Colitis: Evidence to Date
    Glassner, Kerri
    Fan, Christopher
    Irani, Malcolm
    Abraham, Bincy P.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2024, 17 : 337 - 345
  • [4] Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis
    Vermeire, S.
    Peyrin-Biroulet, L.
    Danese, S.
    Dubinsky, M.
    Dulai, P. S.
    Tilg, H.
    Siegmund, B.
    Hisamatsu, T.
    Shan, K.
    Jacobstein, D.
    Cataldi, F.
    Rabbat, C.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1554 - i1555
  • [5] Bowel Urgency and Abdominal Pain in Patients With Moderately to Severely Active Ulcerative Colitis in the Etrasimod ELEVATE UC Clinical Program: A Post Hoc Analysis
    Dubinsky, Marla C.
    Chaparro, Maria
    Armuzzi, Alessandro
    Irving, Peter M.
    Allez, Matthieu
    Panaccione, Remo
    Goetsch, Martina
    Bartolome, Lauren
    Bananis, Eustratios
    Wu, Joseph
    Wosik, Karolina
    Bhattacharjee, Abhishek
    Smith, Christina C.
    Sands, Bruce E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S889 - S890
  • [6] Ulcerative colitis Etrasimod approved from the Age of 16
    Warpakowski, Andrea
    VISCERAL MEDICINE, 2024, 40 (03)
  • [7] Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis
    Jairath, Vipul
    Raine, Tim
    Leahy, Thomas P.
    Potluri, Ravi
    Wosik, Karolina
    Gruben, David
    Cappelleri, Joseph C.
    Hur, Peter
    Bartolome, Lauren
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2025, 14 (04)
  • [8] Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme
    Vermeire, S.
    Rubin, D. T.
    Regueiro, M. D.
    Takeuchi, K.
    Walsh, A.
    Kotze, P. G.
    Charabaty, A.
    Goetsch, M.
    Lazin, K.
    Wu, J.
    Tsamos, G.
    Segovia, M.
    Branquinho, D.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i115 - i117
  • [9] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Dulai, Parambir S.
    Mosli, Mahmoud
    Khanna, Reena
    Levesque, Barrett G.
    Sandborn, William J.
    Feagan, Brian G.
    PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
  • [10] Matching-Adjusted Indirect Comparison of Etrasimod Versus Ozanimod for Clinical Response and Remission Among Patients With Moderately to Severely Active Ulcerative Colitis
    Jairath, Vipul
    Leahy, Thomas P.
    Potluri, Ravi
    Wosik, Karolina
    Gruben, David
    Cappelleri, Joseph C.
    Hur, Peter
    Bartolome, Lauren
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1058 - S1059
12345